Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
SCN1A encodes the Nav1.1 voltage-gated sodium channel alpha subunit, whose dysfunction leads to a spectrum of epileptic disorders including developmental and epileptic encephalopathy (MONDO:0100062). Pathogenic SCN1A variants disrupt neuronal excitability through loss- or gain-of-function effects, causing early-onset, refractory seizures and neurodevelopmental impairment.
The SCN1A–DEE association is classified as Strong based on multiple lines of evidence. Over 50 unrelated DEE probands harbor SCN1A variants: 13 point mutations in 12 probands (PMID:18413471), 38 probands in a cohort of infantile-onset DEE (PMID:34859793), and additional AR cases in affected siblings (PMID:39200163). Several variants are de novo truncating or splice changes with predicted null effect; biallelic missense variants segregate in families with autosomal recessive inheritance. Concordant functional assays across studies further support pathogenicity.
Inheritance is predominantly autosomal dominant with de novo loss-of-function. A subset of SCN1A variants shows autosomal recessive inheritance in consanguineous families, with segregation in two affected siblings (PMID:39200163). Case series include 12 cryptogenic epileptic encephalopathy probands with 13 distinct point mutations (PMID:18413471) and 38 early-infantile-onset DEE probands with SCN1A mutations (PMID:34859793). Variant spectrum spans truncating (nonsense, frameshift), missense, and splice site changes.
Representative variant: c.2803A>T (p.Asn935Tyr) (PMID:39200163).
Multiple electrophysiological studies in heterologous systems demonstrate that SMEI- and DEE-associated SCN1A missense and truncating mutations abolish or severely attenuate Na+ currents (PMID:14672992; PMID:9422778). A knock-in mouse model carrying the recurrent R1648H gain-of-function mutation exhibits spontaneous seizures, interneuron hypoexcitability, and premature mortality, mirroring human DEE (PMID:20100831). Concordance between biophysical defects and clinical severity underscores a loss-of-function mechanism in interneurons leading to network hyperexcitability.
SCN1A variants cause DEE through dominant de novo loss-of-function and, less commonly, recessive hypomorphic alleles. Robust genetic evidence from >50 probands, familial segregation, and extensive functional characterization support a Strong gene-disease relationship. Diagnostic sequencing of SCN1A is recommended in early-onset, drug-resistant epileptic encephalopathy. Early molecular diagnosis informs prognosis, guides avoidance of sodium channel blockers, and enables targeted therapies.
Key Take-home: SCN1A testing is clinically essential for early diagnosis and personalized management of developmental and epileptic encephalopathy.
Gene–Disease AssociationStrongOver 50 unrelated DEE probands with SCN1A variants, including de novo LoF and segregating AR cases; concordant functional data Genetic EvidenceStrong13 point mutations in 12 probands (PMID:18413471), 38 probands (PMID:34859793), segregation in AR siblings (PMID:39200163) Functional EvidenceStrongPatch-clamp studies show SCN1A LoF (PMID:14672992;9422778), R1648H knock-in mouse recapitulates DEE (PMID:20100831) |